In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Cryolife (CRY), with a price target of $32. The company’s shares opened today at $32.44.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 11.2% and a 61.4% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.
Currently, the analyst consensus on Cryolife is a Moderate Buy with an average price target of $33.50, representing a 3.3% upside. In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.05 and a one-year low of $23.99. Currently, Cryolife has an average volume of 182.9K.
Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, David Ashley Lee, the Executive VP, COO & CFO of CRY sold 25,255 shares for a total of $791,749.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the Medical Devices, and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products; On-X products; CardioGenesis cardiac laser therapy; PerClot; and PhotoFix.
